GILD
$156.19-0.75%
as of close, Oct 16, 2026
☾ AH $156.19 -0.75%
GILD SEC filings (2026)
CIK 882095 · Biological Products, (No Diagnostic Substances) (SIC 2836) · incorporated in DE · fiscal year ends in December
3,169 filings on EDGAR since 1994 · 34 annual, 94 quarterly, 317 current · financial statements · earnings
Latest 10-K
Feb 24, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Aug 6, 2026
quarter to Jun 30, 2026
Latest 8-K
Aug 4, 2026
GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS
Last earnings release
Aug 4, 2026
−$6.75 vs −$7.07 · ▼ 2.6%
Filings on file
3,169
since 1994, 2,126 insider forms
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
October 2026
September 2026
- Sep 15Insider saleDickinson Andrew D (Chief Financial Officer) sold 3,000 shares for $436K at $145.29 under a 10b5-1 plan
- Sep 15Insider saleMercier Johanna (Chief Comm & Corp Aff Officer) sold 3,000 shares for $433K at $143.69–$145.29 under a 10b5-1 plan
- Sep 1Insider saleO'Day Daniel Patrick (Chairman & CEO · Director) sold 15,000 shares for $2.2M at $147.51–$149.38 under a 10b5-1 plan
August 2026
- Aug 26Insider saleWELTERS ANTHONY (Director) sold 18,000 shares for $2.7M at $148.24–$148.82 under a 10b5-1 plan
- Aug 20Insider saleBluestone Jeffrey (Director) sold 5,000 shares for $725K at $143.75–$146.36 under a 10b5-1 plan
- Aug 17Insider saleMercier Johanna (Chief Comm & Corp Aff Officer) sold 28,000 shares for $3.9M at $137.37–$138.04 under a 10b5-1 plan
- Aug 17Insider saleDickinson Andrew D (Chief Financial Officer) sold 3,000 shares for $415K at $138.36 under a 10b5-1 plan
- Aug 6ReportQuarterly report, Q2 2026 — revenue $7.80B (+10% y/y), net income −$10.50B, EPS −$8.45
- Aug 4EarningsEarnings release — EPS −$6.75 vs −$7.07 est. (+4.5%); revenue $7.80B (+10% y/y) 2.6%
- Aug 3Insider saleO'Day Daniel Patrick (Chairman & CEO · Director) sold 15,000 shares for $2.0M at $129.66–$131.34 under a 10b5-1 plan
July 2026
- Jul 15Insider saleDickinson Andrew D (Chief Financial Officer) sold 3,000 shares for $390K at $129.93 under a 10b5-1 plan
- Jul 15Insider saleMercier Johanna (Chief Comm & Corp Aff Officer) sold 3,000 shares for $390K at $129.92 under a 10b5-1 plan
- Jul 1Insider saleO'Day Daniel Patrick (Chairman & CEO · Director) sold 15,000 shares for $1.9M at $126.09–$127.08 under a 10b5-1 plan
June 2026
- Jun 15Insider saleDickinson Andrew D (Chief Financial Officer) sold 3,000 shares for $376K at $125.40 under a 10b5-1 plan
- Jun 15Insider saleMercier Johanna (Chief Comm & Corp Aff Officer) sold 3,000 shares for $372K at $123.42–$125.40 under a 10b5-1 plan
- Jun 1Insider saleO'Day Daniel Patrick (Chairman & CEO · Director) sold 15,000 shares for $2.0M at $131.10–$132.97 under a 10b5-1 plan
May 2026
- May 208-K8-K · Material definitive agreement; New financial obligation; Other events
- May 15Insider saleMercier Johanna (Chief Comm & Corp Aff Officer) sold 28,000 shares for $3.7M at $130.29–$132.75 under a 10b5-1 plan
- May 15Insider saleDickinson Andrew D (Chief Financial Officer) sold 3,000 shares for $397K at $132.27 under a 10b5-1 plan
- May 7EarningsEarnings release — EPS $2.03 vs $1.89 est. (+7.4%); revenue $6.96B (+4% y/y) 2.0%
- May 7ReportQuarterly report, Q1 2026 — revenue $6.96B (+4% y/y), net income $2.02B, EPS $1.61
- May 48-K8-K · Shareholder vote results
April 2026
- Apr 28Insider saleO'Day Daniel Patrick (Chairman & CEO · Director) sold 10,000 shares for $1.3M at $128.79–$130.01 under a 10b5-1 plan
- Apr 288-K8-K · GILEAD SCIENCES COMPLETES ACQUISITION OF ARCELLX AHEAD OF POTENTIAL COMMERCIAL LAUNCH OF ANITO-CELRegulation FD disclosure; Other events
- Apr 15Insider saleDickinson Andrew D (Chief Financial Officer) sold 3,000 shares for $423K at $140.96 under a 10b5-1 plan
- Apr 15Insider saleMercier Johanna (Chief Comm & Corp Aff Officer) sold 3,000 shares for $423K at $140.96 under a 10b5-1 plan
March 2026
- Mar 27Insider saleO'Day Daniel Patrick (Chairman & CEO · Director) sold 10,000 shares for $1.4M at $136.82 under a 10b5-1 plan
- Mar 20ProxyProxy · Annual report to shareholders
- Mar 20ProxyProxy · Additional proxy materials
- Mar 20ProxyProxy · Proxy statement
- Mar 16Insider saleDickinson Andrew D (Chief Financial Officer) sold 3,000 shares for $433K at $144.23 under a 10b5-1 plan
- Mar 16Insider saleMercier Johanna (Chief Comm & Corp Aff Officer) sold 3,000 shares for $433K at $144.23 under a 10b5-1 plan
February 2026
- Feb 27Insider saleO'Day Daniel Patrick (Chairman & CEO · Director) sold 10,000 shares for $1.4M at $144.04–$145.71 under a 10b5-1 plan
- Feb 24ReportAnnual report, FY2025 — revenue $29.44B (+2% y/y), net income $8.51B, EPS $6.78
- Feb 238-K8-K · GILEAD SCIENCES TO ACQUIRE ARCELLX TO MAXIMIZE LONG-TERM POTENTIAL OF ANITO-CELMaterial definitive agreement; Regulation FD disclosure
- Feb 17Insider saleMercier Johanna (Chief Comm & Corp Aff Officer) sold 28,000 shares for $4.3M at $154.18–$155.62 under a 10b5-1 plan
- Feb 17Insider saleDickinson Andrew D (Chief Financial Officer) sold 3,000 shares for $463K at $154.43 under a 10b5-1 plan
- Feb 10EarningsEarnings release — EPS $1.86 vs $1.83 est. (+1.6%); revenue $7.92B (+5% y/y) 5.8%
- Feb 5Insider saleO'Day Daniel Patrick (Chairman & CEO · Director) sold 115,640 shares for $17.3M at $150.00 under a 10b5-1 plan
January 2026
- Jan 28Insider saleO'Day Daniel Patrick (Chairman & CEO · Director) sold 10,000 shares for $1.4M at $139.54–$140.24 under a 10b5-1 plan
- Jan 23Insider saleO'Day Daniel Patrick (Chairman & CEO · Director) sold 115,640 shares for $15.6M at $135.00 under a 10b5-1 plan
- Jan 20Insider saleBluestone Jeffrey (Director) sold 5,000 shares for $618K at $123.50 under a 10b5-1 plan
- Jan 15Insider saleDickinson Andrew D (Chief Financial Officer) sold 3,000 shares for $373K at $124.31 under a 10b5-1 plan
- Jan 15Insider saleMercier Johanna (Chief Commercial Officer) sold 3,000 shares for $373K at $124.31 under a 10b5-1 plan
November 2025
October 2025
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $70.7M in 32 sales and bought nothing on the open market; 110 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Oct 1, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorSold · $2.2M · 15,000 sh · 10b5-1 |
| Sep 15, 2026Form 4 | Dickinson Andrew DChief Financial OfficerSold · $436K · 3,000 sh · 10b5-1 |
| Sep 15, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerSold · $433K · 3,000 sh · 10b5-1 |
| Sep 1, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorSold · $2.2M · 15,000 sh · 10b5-1 |
| Aug 26, 2026Form 4 | WELTERS ANTHONYDirectorSold · $2.7M · 18,000 sh · 10b5-1 |
| Aug 20, 2026Form 4 | Bluestone JeffreyDirectorSold · $725K · 5,000 sh · 10b5-1 |
| Aug 17, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerSold · $3.9M · 28,000 sh · 10b5-1 |
| Aug 17, 2026Form 4 | Dickinson Andrew DChief Financial OfficerSold · $415K · 3,000 sh · 10b5-1 |
| Aug 3, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorSold · $2.0M · 15,000 sh · 10b5-1 |
| Jul 15, 2026Form 4 | Dickinson Andrew DChief Financial OfficerSold · $390K · 3,000 sh · 10b5-1 |
| Jul 15, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerSold · $390K · 3,000 sh · 10b5-1 |
| Jul 1, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorSold · $1.9M · 15,000 sh · 10b5-1 |
| Jun 15, 2026Form 4 | Dickinson Andrew DChief Financial OfficerSold · $376K · 3,000 sh · 10b5-1 |
| Jun 15, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerSold · $372K · 3,000 sh · 10b5-1 |
| Jun 1, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorSold · $2.0M · 15,000 sh · 10b5-1 |
| May 15, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerSold · $3.7M · 28,000 sh · 10b5-1 |
| May 15, 2026Form 4 | Dickinson Andrew DChief Financial OfficerSold · $397K · 3,000 sh · 10b5-1 |
| Apr 28, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorSold · $1.3M · 10,000 sh · 10b5-1 |
| Apr 15, 2026Form 4 | Dickinson Andrew DChief Financial OfficerSold · $423K · 3,000 sh · 10b5-1 |
| Apr 15, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerSold · $423K · 3,000 sh · 10b5-1 |
| Mar 27, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorSold · $1.4M · 10,000 sh · 10b5-1 |
| Mar 16, 2026Form 4 | Dickinson Andrew DChief Financial OfficerSold · $433K · 3,000 sh · 10b5-1 |
| Mar 16, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerSold · $433K · 3,000 sh · 10b5-1 |
| Feb 27, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorSold · $1.4M · 10,000 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerSold · $4.3M · 28,000 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Dickinson Andrew DChief Financial OfficerSold · $463K · 3,000 sh · 10b5-1 |
| Feb 5, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorSold · $17.3M · 115,640 sh · 10b5-1 |
| Jan 28, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorSold · $1.4M · 10,000 sh · 10b5-1 |
| Jan 23, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorSold · $15.6M · 115,640 sh · 10b5-1 |
| Jan 20, 2026Form 4 | Bluestone JeffreyDirectorSold · $618K · 5,000 sh · 10b5-1 |
| Jan 15, 2026Form 4 | Dickinson Andrew DChief Financial OfficerSold · $373K · 3,000 sh · 10b5-1 |
| Jan 15, 2026Form 4 | Mercier JohannaChief Commercial OfficerSold · $373K · 3,000 sh · 10b5-1 |
Awards, exercises, withholding and plan purchases · 110 transactions
| Date | Insider |
|---|---|
| Sep 22, 2026Form 4 | Burkhart ErinSVP, ControllershipTax withholding · $117K · 768 sh |
| Sep 22, 2026Form 4 | Burkhart ErinSVP, ControllershipExercise or conversion · — · 2,223 sh |
| Sep 22, 2026Form 4 | Burkhart ErinSVP, ControllershipExercise or conversion · Restricted Stock Unit · — · 2,223 sh |
| Sep 10, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorTax withholding · $613K · 4,230 sh |
| Sep 10, 2026Form 4 | Dickinson Andrew DChief Financial OfficerTax withholding · $195K · 1,347 sh |
| Sep 10, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerTax withholding · $195K · 1,347 sh |
| Sep 10, 2026Form 4 | Cain Wettan Keeley MEVP Gen Counsel, Legal & CompTax withholding · $41K · 285 sh |
| Sep 10, 2026Form 4 | Berger DietmarChief Medical OfficerTax withholding · $38K · 263 sh |
| Sep 10, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorExercise or conversion · — · 8,780 sh |
| Sep 10, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorExercise or conversion · Restricted Stock Unit · — · 8,780 sh |
| Sep 10, 2026Form 4 | Dickinson Andrew DChief Financial OfficerExercise or conversion · — · 2,797 sh |
| Sep 10, 2026Form 4 | Dickinson Andrew DChief Financial OfficerExercise or conversion · Restricted Stock Unit · — · 2,797 sh |
| Sep 10, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerExercise or conversion · — · 2,797 sh |
| Sep 10, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerExercise or conversion · Restricted Stock Unit · — · 2,797 sh |
| Sep 10, 2026Form 4 | Cain Wettan Keeley MEVP Gen Counsel, Legal & CompExercise or conversion · — · 590 sh |
| Sep 10, 2026Form 4 | Cain Wettan Keeley MEVP Gen Counsel, Legal & CompExercise or conversion · Restricted Stock Unit · — · 590 sh |
| Sep 10, 2026Form 4 | Berger DietmarChief Medical OfficerExercise or conversion · — · 533 sh |
| Sep 10, 2026Form 4 | Berger DietmarChief Medical OfficerExercise or conversion · Restricted Stock Unit · — · 533 sh |
| Aug 26, 2026Form 4 | WELTERS ANTHONYDirectorExercise or conversion · $1.1M · 18,000 sh · 10b5-1 |
| Aug 26, 2026Form 4 | WELTERS ANTHONYDirectorExercise or conversion · Non-qualified Stock Option… · $0 · 18,000 sh · 10b5-1 |
| Aug 20, 2026Form 4 | Bluestone JeffreyDirectorExercise or conversion · $335K · 5,000 sh · 10b5-1 |
| Aug 20, 2026Form 4 | Bluestone JeffreyDirectorExercise or conversion · Non-qualified Stock Option… · $0 · 5,000 sh · 10b5-1 |
| Aug 17, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerExercise or conversion · $1.7M · 25,000 sh · 10b5-1 |
| Aug 17, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerExercise or conversion · Non-qualified Stock Option… · $0 · 25,000 sh · 10b5-1 |
| Aug 10, 2026Form 4 | Cain Wettan Keeley MEVP Gen Counsel, Legal & CompTax withholding · $387K · 2,908 sh |
| Aug 10, 2026Form 4 | Cain Wettan Keeley MEVP Gen Counsel, Legal & CompExercise or conversion · — · 6,002 sh |
| Aug 10, 2026Form 4 | Cain Wettan Keeley MEVP Gen Counsel, Legal & CompExercise or conversion · Restricted Stock Unit · — · 6,002 sh |
| Jun 10, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorTax withholding · $512K · 4,213 sh |
| Jun 10, 2026Form 4 | Dickinson Andrew DChief Financial OfficerTax withholding · $163K · 1,341 sh |
| Jun 10, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerTax withholding · $163K · 1,341 sh |
| Jun 10, 2026Form 4 | Cain Wettan Keeley MEVP Gen Counsel, Legal & CompTax withholding · $34K · 283 sh |
| Jun 10, 2026Form 4 | Berger DietmarChief Medical OfficerTax withholding · $32K · 263 sh |
| Jun 10, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorExercise or conversion · — · 8,779 sh |
| Jun 10, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorExercise or conversion · Restricted Stock Unit · — · 8,779 sh |
| Jun 10, 2026Form 4 | Dickinson Andrew DChief Financial OfficerExercise or conversion · — · 2,796 sh |
| Jun 10, 2026Form 4 | Dickinson Andrew DChief Financial OfficerExercise or conversion · Restricted Stock Unit · — · 2,796 sh |
| Jun 10, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerExercise or conversion · — · 2,796 sh |
| Jun 10, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerExercise or conversion · Restricted Stock Unit · — · 2,796 sh |
| Jun 10, 2026Form 4 | Cain Wettan Keeley MEVP Gen Counsel, Legal & CompExercise or conversion · — · 589 sh |
| Jun 10, 2026Form 4 | Cain Wettan Keeley MEVP Gen Counsel, Legal & CompExercise or conversion · Restricted Stock Unit · — · 589 sh |
| Jun 10, 2026Form 4 | Berger DietmarChief Medical OfficerExercise or conversion · — · 533 sh |
| Jun 10, 2026Form 4 | Berger DietmarChief Medical OfficerExercise or conversion · Restricted Stock Unit · — · 533 sh |
| May 15, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerExercise or conversion · $1.7M · 25,000 sh · 10b5-1 |
| May 15, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerExercise or conversion · Non-qualified Stock Option… · $0 · 25,000 sh · 10b5-1 |
| Apr 30, 2026Form 4 | MANWANI HARISHDirectorTax withholding · $29K · 224 sh |
| Apr 30, 2026Form 4 | Bluestone JeffreyDirectorAward · Non-qualified Stock Option… · $0 · 4,884 sh |
| Apr 30, 2026Form 4 | BARTON JACQUELINE KDirectorAward · Non-qualified Stock Option… · $0 · 4,884 sh |
| Apr 30, 2026Form 4 | LOVE TED WDirectorAward · Non-qualified Stock Option… · $0 · 4,884 sh |
| Apr 30, 2026Form 4 | WELTERS ANTHONYDirectorAward · Non-qualified Stock Option… · $0 · 4,884 sh |
| Apr 30, 2026Form 4 | Rodriguez JavierDirectorAward · Non-qualified Stock Option… · $0 · 4,884 sh |
| Apr 30, 2026Form 4 | MANWANI HARISHDirectorAward · Non-qualified Stock Option… · $0 · 4,884 sh |
| Apr 30, 2026Form 4 | Kramer Kelly A.DirectorAward · Non-qualified Stock Option… · $0 · 4,884 sh |
| Apr 30, 2026Form 4 | Horning SandraDirectorAward · Non-qualified Stock Option… · $0 · 4,884 sh |
| Apr 30, 2026Form 4 | Bluestone JeffreyDirectorAward · $0 · 1,146 sh |
| Apr 30, 2026Form 4 | BARTON JACQUELINE KDirectorAward · $0 · 1,146 sh |
| Apr 30, 2026Form 4 | LOVE TED WDirectorAward · $0 · 1,146 sh |
| Apr 30, 2026Form 4 | WELTERS ANTHONYDirectorAward · $0 · 1,146 sh |
| Apr 30, 2026Form 4 | Rodriguez JavierDirectorAward · $0 · 1,146 sh |
| Apr 30, 2026Form 4 | MANWANI HARISHDirectorAward · $0 · 1,146 sh |
| Apr 30, 2026Form 4 | Kramer Kelly A.DirectorAward · Restricted Stock Unit · $0 · 1,146 sh |
| Apr 30, 2026Form 4 | Horning SandraDirectorAward · $0 · 1,146 sh |
| Mar 10, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorTax withholding · $1.5M · 9,767 sh |
| Mar 10, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerTax withholding · $478K · 3,216 sh |
| Mar 10, 2026Form 4 | Dickinson Andrew DChief Financial OfficerTax withholding · $468K · 3,147 sh |
| Mar 10, 2026Form 4 | Berger DietmarChief Medical OfficerTax withholding · $158K · 1,063 sh |
| Mar 10, 2026Form 4 | Cain Wettan Keeley MEVP Gen Counsel, Legal & CompTax withholding · $90K · 606 sh |
| Mar 10, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorAward · Non-qualified Stock Option… · $0 · 122,755 sh |
| Mar 10, 2026Form 4 | Dickinson Andrew DChief Financial OfficerAward · Non-qualified Stock Option… · $0 · 35,880 sh |
| Mar 10, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerAward · Non-qualified Stock Option… · $0 · 35,880 sh |
| Mar 10, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorAward · Restricted Stock Unit · — · 32,815 sh |
| Mar 10, 2026Form 4 | Berger DietmarChief Medical OfficerAward · Non-qualified Stock Option… · $0 · 31,475 sh |
| Mar 10, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorExercise or conversion · — · 20,026 sh |
| Mar 10, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorExercise or conversion · Restricted Stock Unit · — · 20,026 sh |
| Mar 10, 2026Form 4 | Cain Wettan Keeley MEVP Gen Counsel, Legal & CompAward · Non-qualified Stock Option… · $0 · 18,885 sh |
| Mar 10, 2026Form 4 | Dickinson Andrew DChief Financial OfficerAward · Restricted Stock Unit · — · 9,590 sh |
| Mar 10, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerAward · Restricted Stock Unit · — · 9,590 sh |
| Mar 10, 2026Form 4 | Berger DietmarChief Medical OfficerAward · Restricted Stock Unit · — · 8,415 sh |
| Mar 10, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerExercise or conversion · — · 6,617 sh |
| Mar 10, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerExercise or conversion · Restricted Stock Unit · — · 6,617 sh |
| Mar 10, 2026Form 4 | Dickinson Andrew DChief Financial OfficerExercise or conversion · — · 6,469 sh |
| Mar 10, 2026Form 4 | Dickinson Andrew DChief Financial OfficerExercise or conversion · Restricted Stock Unit · — · 6,469 sh |
| Mar 10, 2026Form 4 | Burkhart ErinSVP, ControllershipAward · Non-qualified Stock Option… · $0 · 5,455 sh |
| Mar 10, 2026Form 4 | Cain Wettan Keeley MEVP Gen Counsel, Legal & CompAward · Restricted Stock Unit · — · 5,050 sh |
| Mar 10, 2026Form 4 | Burkhart ErinSVP, ControllershipAward · Restricted Stock Unit · — · 2,355 sh |
| Mar 10, 2026Form 4 | Berger DietmarChief Medical OfficerExercise or conversion · — · 2,133 sh |
| Mar 10, 2026Form 4 | Berger DietmarChief Medical OfficerExercise or conversion · Restricted Stock Unit · — · 2,133 sh |
| Mar 10, 2026Form 4 | Cain Wettan Keeley MEVP Gen Counsel, Legal & CompExercise or conversion · — · 1,246 sh |
| Mar 10, 2026Form 4 | Cain Wettan Keeley MEVP Gen Counsel, Legal & CompExercise or conversion · Restricted Stock Unit · — · 1,246 sh |
| Feb 27, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorAward · $0 · 38,396 sh · 10b5-1 |
| Feb 27, 2026Form 4 | Dickinson Andrew DChief Financial OfficerAward · $0 · 11,090 sh |
| Feb 27, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerAward · $0 · 11,090 sh |
| Feb 27, 2026Form 4 | Berger DietmarChief Medical OfficerAward · $0 · 8,530 sh |
| Feb 27, 2026Form 4 | Cain Wettan Keeley MEVP Gen Counsel, Legal & CompAward · $0 · 470 sh |
| Feb 17, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerExercise or conversion · $1.7M · 25,000 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerExercise or conversion · Non-qualified Stock Option… · $0 · 25,000 sh · 10b5-1 |
| Feb 5, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorExercise or conversion · $7.6M · 115,640 sh · 10b5-1 |
| Feb 5, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorExercise or conversion · Non-qualified Stock Option… · $0 · 115,640 sh · 10b5-1 |
| Feb 3, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorTax withholding · $10.7M · 74,461 sh |
| Feb 3, 2026Form 4 | Dickinson Andrew DChief Financial OfficerTax withholding · $3.6M · 24,802 sh |
| Feb 3, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerTax withholding · $3.6M · 24,800 sh |
| Feb 3, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorAward · $0 · 131,675 sh |
| Feb 3, 2026Form 4 | Dickinson Andrew DChief Financial OfficerAward · $0 · 44,867 sh |
| Feb 3, 2026Form 4 | Mercier JohannaChief Comm & Corp Aff OfficerAward · $0 · 44,867 sh |
| Jan 23, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorExercise or conversion · $7.6M · 115,640 sh · 10b5-1 |
| Jan 23, 2026Form 4 | O'Day Daniel PatrickChairman & CEO · DirectorExercise or conversion · Non-qualified Stock Option… · $0 · 115,640 sh · 10b5-1 |
| Jan 20, 2026Form 4 | Bluestone JeffreyDirectorExercise or conversion · $337K · 5,000 sh · 10b5-1 |
| Jan 20, 2026Form 4 | Bluestone JeffreyDirectorExercise or conversion · Non-qualified Stock Option… · $0 · 5,000 sh · 10b5-1 |
| Jan 2, 2026Form 4 | Berger DietmarChief Medical OfficerTax withholding · $844K · 6,944 sh |
| Jan 2, 2026Form 4 | Berger DietmarChief Medical OfficerExercise or conversion · — · 16,326 sh |
| Jan 2, 2026Form 4 | Berger DietmarChief Medical OfficerExercise or conversion · Restricted Stock Unit · — · 16,326 sh |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 13 filings
| Filed | What it is |
|---|---|
| Aug 6, 202610-Q | Quarterly report, Q2 2026 — revenue $7.80B (+10% y/y), net income −$10.50B, EPS −$8.45 |
| Aug 4, 20268-K | Earnings release — EPS −$6.75 vs −$7.07 est. (+4.5%); revenue $7.80B (+10% y/y) 2.6% |
| May 20, 20268-K | Material definitive agreement; New financial obligation; Other events |
| May 7, 202610-Q | Quarterly report, Q1 2026 — revenue $6.96B (+4% y/y), net income $2.02B, EPS $1.61 |
| May 7, 20268-K | Earnings release — EPS $2.03 vs $1.89 est. (+7.4%); revenue $6.96B (+4% y/y) 2.0% |
| May 4, 20268-K | Shareholder vote results |
| Apr 28, 20268-K | GILEAD SCIENCES COMPLETES ACQUISITION OF ARCELLX AHEAD OF POTENTIAL COMMERCIAL LAUNCH OF ANITO-CELRegulation FD disclosure; Other events |
| Mar 20, 2026ARS | Annual report to shareholders |
| Mar 20, 2026DEFA14A | Additional proxy materials |
| Mar 20, 2026DEF 14A | Proxy statement |
| Feb 24, 202610-K | Annual report, FY2025 — revenue $29.44B (+2% y/y), net income $8.51B, EPS $6.78 |
| Feb 23, 20268-K | GILEAD SCIENCES TO ACQUIRE ARCELLX TO MAXIMIZE LONG-TERM POTENTIAL OF ANITO-CELMaterial definitive agreement; Regulation FD disclosure |
| Feb 10, 20268-K | Earnings release — EPS $1.86 vs $1.83 est. (+1.6%); revenue $7.92B (+5% y/y) 5.8% |
2025 · 18 filings
| Filed | What it is |
|---|---|
| Nov 19, 20258-K | Directors or officers; compensation |
| Nov 7, 202510-Q | Quarterly report, Q3 2025 — revenue $7.77B (+3% y/y), net income $3.05B, EPS $2.43 |
| Oct 30, 20258-K | Earnings release — EPS $2.47 vs $2.15 est. (+14.9%); revenue $7.77B (+3% y/y) 1.1% |
| Oct 6, 20258-K | Regulation FD disclosure |
| Aug 14, 20258-K | Directors or officers; compensation |
| Aug 7, 202510-Q | Quarterly report, Q2 2025 — revenue $7.08B (+2% y/y), net income $1.96B, EPS $1.56 |
| Aug 7, 20258-K | Results of operations |
| Aug 4, 20258-K | Charter, bylaws or fiscal-year change |
| May 8, 20258-K | Shareholder vote results |
| May 7, 202510-Q | Quarterly report, Q1 2025 — revenue $6.67B (−0% y/y), net income $1.31B, EPS $1.04 |
| Apr 24, 20258-K | Results of operations |
| Apr 7, 2025PX14A6G | Shareholder exempt solicitation |
| Mar 27, 2025ARS | Annual report to shareholders |
| Mar 27, 2025DEFA14A | Additional proxy materials |
| Mar 27, 2025DEF 14A | Proxy statement |
| Mar 12, 20258-K | Directors or officers; compensation |
| Feb 28, 202510-K | Annual report, FY2024 — revenue $28.75B (+6% y/y), net income $480.0M, EPS $0.38 |
| Feb 11, 20258-K | Results of operations |
2024 · 20 filings
| Filed | What it is |
|---|---|
| Dec 13, 20248-K/A | Directors or officers; compensation |
| Nov 20, 20248-K | Material definitive agreement; New financial obligation; Other events |
| Nov 12, 202410-Q | Quarterly report, Q3 2024 — revenue $7.54B (+7% y/y), net income $1.25B, EPS $1.00 |
| Nov 6, 20248-K | Results of operations |
| Aug 8, 202410-Q | Quarterly report, Q2 2024 — revenue $6.95B (+5% y/y), net income $1.61B, EPS $1.29 |
| Aug 8, 20248-K | Results of operations |
| Jul 17, 20248-K | Directors or officers; compensation |
| May 9, 20248-K | Charter, bylaws or fiscal-year change; Shareholder vote results |
| May 8, 202410-Q | Quarterly report, Q1 2024 — revenue $6.69B (+5% y/y), net income −$4.17B, EPS −$3.34 |
| Apr 25, 20248-K | Results of operations |
| Mar 28, 2024ARS | Annual report to shareholders |
| Mar 28, 2024DEFA14A | Additional proxy materials |
| Mar 28, 2024DEF 14A | Proxy statement |
| Mar 22, 20248-K | Regulation FD disclosure; Other events |
| Mar 18, 2024PRE 14A | Preliminary proxy statement |
| Mar 14, 20248-K | Directors or officers; compensation |
| Feb 23, 202410-K | Annual report, FY2023 — revenue $27.12B (−1% y/y), net income $5.67B, EPS $4.50 |
| Feb 12, 20248-K | Material definitive agreement; Other events |
| Feb 6, 20248-K | Results of operations |
| Feb 2, 20248-K | Directors or officers; compensation |
2023 · 17 filings — 8 × 8-K, 3 × 10-Q, 2 × PX14A6G and 4 other forms
| Filed | What it is |
|---|---|
| Nov 7, 202310-Q | Quarterly report, Q3 2023 — revenue $7.05B (+0% y/y), net income $2.18B, EPS $1.73 |
| Aug 4, 202310-Q | Quarterly report, Q2 2023 — revenue $6.60B (+5% y/y), net income $1.04B, EPS $0.83 |
| May 3, 202310-Q | Quarterly report, Q1 2023 — revenue $6.35B (−4% y/y), net income $1.01B, EPS $0.80 |
| Apr 6, 2023PX14A6G | Shareholder exempt solicitation |
| Apr 5, 2023DEFR14A | Proxy statements |
| Mar 29, 2023PX14A6G | Shareholder exempt solicitation |
| Mar 23, 2023DEF 14A | Proxy statement |
| Mar 23, 2023DEFA14A | Additional proxy materials |
| Feb 22, 202310-K | Annual report, FY2022 — revenue $27.28B (−0% y/y), net income $4.59B, EPS $3.64 |
8 current reports (8-K) not listed; the year is on EDGAR.
2022 · 20 filings — 11 × 8-K, 3 × 10-Q, 3 × PX14A6G and 3 other forms
| Filed | What it is |
|---|---|
| Nov 2, 202210-Q | Quarterly report, Q3 2022 — revenue $7.04B (−5% y/y), net income $1.79B, EPS $1.42 |
| Aug 8, 202210-Q | Quarterly report, Q2 2022 — revenue $6.26B (+1% y/y), net income $1.14B, EPS $0.91 |
| May 4, 202210-Q | Quarterly report, Q1 2022 — revenue $6.59B (+3% y/y), net income $19.0M, EPS $0.02 |
| Apr 11, 2022PX14A6G | Shareholder exempt solicitation |
| Apr 7, 2022PX14A6G | Shareholder exempt solicitation |
| Apr 5, 2022PX14A6G | Shareholder exempt solicitation |
| Mar 24, 2022DEFA14A | Additional proxy materials |
| Mar 24, 2022DEF 14A | Proxy statement |
| Feb 23, 202210-K | Annual report, FY2021 — revenue $27.30B (+11% y/y), net income $6.22B, EPS $4.93 |
11 current reports (8-K) not listed; the year is on EDGAR.
2021 · 14 filings — 6 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms
| Filed | What it is |
|---|---|
| Nov 3, 202110-Q | Quarterly report, Q3 2021 — revenue $7.42B (+13% y/y), net income $2.59B, EPS $2.05 |
| Aug 5, 202110-Q | Quarterly report, Q2 2021 — revenue $6.22B (+21% y/y), net income $1.52B, EPS $1.21 |
| May 6, 202110-Q | Quarterly report, Q1 2021 — revenue $6.42B (+16% y/y), net income $1.73B, EPS $1.37 |
| Apr 19, 2021PX14A6G | Shareholder exempt solicitation |
| Mar 30, 2021DEFA14A | Additional proxy materials |
| Mar 30, 2021DEF 14A | Proxy statement |
| Feb 25, 202110-K | Annual report, FY2020 — revenue $24.69B (+10% y/y), net income $123.0M, EPS $0.10 |
7 current reports (8-K) not listed; the year is on EDGAR.
2020 · 22 filings — 14 × 8-K, 3 × 10-Q, 2 × DEFA14A and 3 other forms
| Filed | What it is |
|---|---|
| Nov 4, 202010-Q | Quarterly report, Q3 2020 — revenue $6.58B (+17% y/y), net income $360.0M, EPS $0.29 |
| Aug 6, 202010-Q | Quarterly report, Q2 2020 — revenue $5.14B (−10% y/y), net income −$3.34B, EPS −$2.66 |
| May 6, 202010-Q | Quarterly report, Q1 2020 — revenue $5.55B (+5% y/y), net income $1.55B, EPS $1.22 |
| Apr 15, 2020DEFA14A | Additional proxy materials |
| Mar 26, 2020PX14A6G | Shareholder exempt solicitation |
| Mar 24, 2020DEFA14A | Additional proxy materials |
| Mar 24, 2020DEF 14A | Proxy statement |
| Feb 25, 202010-K | Annual report, FY2019 — revenue $22.45B (+1% y/y), net income $5.39B, EPS $4.22 |
14 current reports (8-K) not listed; the year is on EDGAR.
2019 · 21 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms
| Filed | What it is |
|---|---|
| Nov 5, 201910-Q | Quarterly report, Q3 2019 — revenue $5.60B (+0% y/y), net income −$1.17B, EPS −$0.92 |
| Aug 6, 201910-Q | Quarterly report, Q2 2019 — revenue $5.68B (+1% y/y), net income $1.88B, EPS $1.47 |
| May 8, 201910-Q | Quarterly report, Q1 2019 — revenue $5.28B (+4% y/y), net income $1.98B, EPS $1.54 |
| Apr 18, 201910-K/A | Annual report, amended |
| Mar 25, 2019DEFA14A | Additional proxy materials |
| Mar 25, 2019DEF 14A | Proxy statement |
| Mar 15, 2019PRE 14A | Preliminary proxy statement |
| Feb 26, 201910-K | Annual report, FY2018 — revenue $22.13B (−15% y/y), net income $5.46B |
13 current reports (8-K) not listed; the year is on EDGAR.
2018 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 6, 201810-Q | Quarterly report, Q3 2018 — revenue $5.60B (−14% y/y), net income $2.10B, EPS $1.60 |
| Aug 6, 201810-Q | Quarterly report, Q2 2018 — revenue $5.65B (−21% y/y), net income $1.82B, EPS $1.39 |
| May 9, 201810-Q | Quarterly report, Q1 2018 — revenue $5.09B (−22% y/y), net income $1.54B, EPS $1.17 |
| Mar 26, 2018DEFA14A | Additional proxy materials |
| Mar 26, 2018DEF 14A | Proxy statement |
| Feb 27, 201810-K | Annual report, FY2017 — revenue $26.11B (−14% y/y), net income $4.63B, EPS $3.51 |
10 current reports (8-K) not listed; the year is on EDGAR.
2017 · 20 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Nov 7, 201710-Q | Quarterly report, Q3 2017 — revenue $6.51B (−13% y/y), net income $2.72B, EPS $2.06 |
| Aug 7, 201710-Q | Quarterly report, Q2 2017 — revenue $7.14B (−8% y/y), net income $3.07B, EPS $2.33 |
| May 10, 201710-Q | Quarterly report, Q1 2017 — revenue $6.50B (−17% y/y), net income $2.70B, EPS $2.05 |
| Mar 27, 2017DEFA14A | Additional proxy materials |
| Mar 27, 2017DEF 14A | Proxy statement |
| Feb 27, 201710-K | Annual report, FY2016 — revenue $30.39B (−7% y/y), net income $13.50B, EPS $9.94 |
14 current reports (8-K) not listed; the year is on EDGAR.
2016 · 18 filings — 10 × 8-K, 3 × 10-Q, 2 × DEFA14A and 3 other forms
Counted, not listed; the year is on EDGAR.
2015 · 17 filings — 8 × 8-K, 3 × 10-Q, 3 × PX14A6G and 3 other forms
Counted, not listed; the year is on EDGAR.
2014 · 19 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2013 · 18 filings — 8 × 8-K, 3 × 10-Q, 2 × DEFA14A and 5 other forms
Counted, not listed; the year is on EDGAR.
2012 · 21 filings — 13 × 8-K, 3 × 10-Q, 2 × DEFA14A and 3 other forms
Counted, not listed; the year is on EDGAR.
2011 · 27 filings — 19 × 8-K, 3 × 10-Q, 2 × DEFA14A and 3 other forms
Counted, not listed; the year is on EDGAR.
2010 · 22 filings — 16 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2009 · 21 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2008 · 26 filings — 19 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2007 · 27 filings — 18 × 8-K, 3 × 10-Q, 3 × 8-K/A and 3 other forms
Counted, not listed; the year is on EDGAR.
2006 · 27 filings — 19 × 8-K, 3 × 10-Q, 2 × 8-K/A and 3 other forms
Counted, not listed; the year is on EDGAR.
2005 · 24 filings — 17 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2004 · 16 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2003 · 15 filings — 6 × 8-K, 3 × 10-Q, 2 × 10-K/A and 3 other forms
Counted, not listed; the year is on EDGAR.
2002 · 11 filings — 4 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2001 · 6 filings — 3 × 10-Q, 1 × 10-K, 1 × 8-K and 1 other form
Counted, not listed; the year is on EDGAR.
2000 · 7 filings — 3 × 10-Q, 2 × 8-K, 1 × 10-K405 and 1 other form
Counted, not listed; the year is on EDGAR.
1999 · 10 filings — 4 × 8-K, 3 × 10-Q, 1 × 10-K405 and 2 other forms
Counted, not listed; the year is on EDGAR.
1998 · 5 filings — 3 × 10-Q, 1 × 10-K405, 1 × DEF 14A
Counted, not listed; the year is on EDGAR.
1997 · 6 filings — 3 × 10-Q, 1 × 10-K405, 1 × 10-Q/A and 1 other form
Counted, not listed; the year is on EDGAR.
1996 · 3 filings — 3 × 10-Q
Counted, not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 125 filings — 68 × 4, 32 × 144, 3 × 13F-HR and 13 other forms
| Filed | What it is |
|---|---|
| Oct 15, 2026144 | Notice of proposed sale (Form 144) |
| Oct 15, 2026144 | Notice of proposed sale (Form 144) |
| Oct 2, 20264 | Insider transaction (Form 4) |
| Sep 23, 20264 | Insider transaction (Form 4) |
| Sep 16, 20264 | Insider transaction (Form 4) |
| Sep 16, 20264 | Insider transaction (Form 4) |
| Sep 15, 2026144 | Notice of proposed sale (Form 144) |
| Sep 15, 2026144 | Notice of proposed sale (Form 144) |
| Sep 11, 20264 | Insider transaction (Form 4) |
| Sep 11, 20264 | Insider transaction (Form 4) |
| Sep 11, 20264 | Insider transaction (Form 4) |
| Sep 11, 20264 | Insider transaction (Form 4) |
| Sep 11, 20264 | Insider transaction (Form 4) |
| Sep 2, 20264 | Insider transaction (Form 4) |
| Aug 27, 20264 | Insider transaction (Form 4) |
| Aug 26, 2026144 | Notice of proposed sale (Form 144) |
| Aug 26, 2026N-PX | Other filings |
| Aug 21, 20264 | Insider transaction (Form 4) |
| Aug 20, 2026144 | Notice of proposed sale (Form 144) |
| Aug 18, 20264 | Insider transaction (Form 4) |
| Aug 18, 20264 | Insider transaction (Form 4) |
| Aug 17, 2026144 | Notice of proposed sale (Form 144) |
| Aug 17, 2026144 | Notice of proposed sale (Form 144) |
| Aug 11, 20264 | Insider transaction (Form 4) |
| Aug 7, 2026SCHEDULE 13D/A | Other filings |
The newest 25 of 125 shown; the full year is on EDGAR.
2025 · 133 filings — 76 × 4, 38 × 144, 6 × SCHEDULE 13D/A and 4 other forms
| Filed | What it is |
|---|---|
| Dec 30, 20254 | Insider transaction (Form 4) |
| Dec 29, 2025144 | Notice of proposed sale (Form 144) |
| Dec 16, 20254 | Insider transaction (Form 4) |
| Dec 16, 20254 | Insider transaction (Form 4) |
| Dec 15, 2025144 | Notice of proposed sale (Form 144) |
| Dec 15, 2025144 | Notice of proposed sale (Form 144) |
| Dec 11, 20254 | Insider transaction (Form 4) |
| Dec 11, 20254 | Insider transaction (Form 4) |
| Dec 11, 20254 | Insider transaction (Form 4) |
| Dec 1, 20254 | Insider transaction (Form 4) |
| Dec 1, 20254 | Insider transaction (Form 4) |
| Dec 1, 20254 | Insider transaction (Form 4) |
| Dec 1, 20254 | Insider transaction (Form 4) |
| Nov 28, 2025144 | Notice of proposed sale (Form 144) |
| Nov 28, 2025144 | Notice of proposed sale (Form 144) |
| Nov 26, 2025144 | Notice of proposed sale (Form 144) |
| Nov 18, 20254 | Insider transaction (Form 4) |
| Nov 18, 20254 | Insider transaction (Form 4) |
| Nov 17, 2025144 | Notice of proposed sale (Form 144) |
| Nov 17, 2025144 | Notice of proposed sale (Form 144) |
| Nov 13, 20254 | Insider transaction (Form 4) |
| Nov 13, 2025144 | Notice of proposed sale (Form 144) |
| Nov 13, 202513F-HR | Other filings |
| Nov 12, 2025144 | Notice of proposed sale (Form 144) |
| Nov 5, 2025SCHEDULE 13D/A | Other filings |
The newest 25 of 133 shown; the full year is on EDGAR.
2024 · 114 filings — 67 × 4, 17 × 144, 5 × SC 13G/A and 11 other forms
| Filed | What it is |
|---|---|
| Dec 23, 20244 | Insider transaction (Form 4) |
| Dec 23, 2024SCHEDULE 13D/A | Other filings |
| Dec 19, 20244 | Insider transaction (Form 4) |
| Dec 19, 2024SCHEDULE 13G/A | Other filings |
| Dec 17, 20244 | Insider transaction (Form 4) |
| Dec 16, 20244 | Insider transaction (Form 4) |
| Dec 16, 2024144 | Notice of proposed sale (Form 144) |
| Dec 11, 20244 | Insider transaction (Form 4) |
| Dec 11, 20244 | Insider transaction (Form 4) |
| Dec 11, 20244 | Insider transaction (Form 4) |
| Dec 11, 20244 | Insider transaction (Form 4) |
| Dec 11, 20244 | Insider transaction (Form 4) |
| Dec 11, 20244 | Insider transaction (Form 4) |
| Dec 3, 20244 | Insider transaction (Form 4) |
| Nov 29, 20244 | Insider transaction (Form 4) |
| Nov 29, 2024144 | Notice of proposed sale (Form 144) |
| Nov 27, 20244 | Insider transaction (Form 4) |
| Nov 27, 2024144 | Notice of proposed sale (Form 144) |
| Nov 26, 2024144 | Notice of proposed sale (Form 144) |
| Nov 15, 2024424B5 | Prospectus supplement |
| Nov 13, 2024FWP | Free writing prospectus |
| Nov 13, 2024424B5 | Prospectus supplement |
| Nov 7, 20244 | Insider transaction (Form 4) |
| Nov 7, 20244 | Insider transaction (Form 4) |
| Nov 6, 2024144 | Notice of proposed sale (Form 144) |
The newest 25 of 114 shown; the full year is on EDGAR.
2023 · 87 filings — 60 × 4, 6 × SC 13G/A, 4 × 144 and 10 other forms
Counted, not listed; the year is on EDGAR.
2022 · 79 filings — 64 × 4, 7 × SC 13G/A, 3 × 3 and 3 other forms
Counted, not listed; the year is on EDGAR.
2021 · 62 filings — 54 × 4, 5 × SC 13G/A, 1 × 4/A and 2 other forms
Counted, not listed; the year is on EDGAR.
2020 · 111 filings — 64 × 4, 10 × SC TO-T/A, 9 × SC TO-C and 12 other forms
Counted, not listed; the year is on EDGAR.
2019 · 76 filings — 59 × 4, 4 × 3, 4 × CT ORDER and 4 other forms
Counted, not listed; the year is on EDGAR.
2018 · 95 filings — 77 × 4, 9 × CT ORDER, 5 × 3 and 3 other forms
Counted, not listed; the year is on EDGAR.
2017 · 109 filings — 81 × 4, 6 × SC TO-T/A, 5 × CT ORDER and 11 other forms
Counted, not listed; the year is on EDGAR.
2016 · 110 filings — 90 × 4, 10 × CT ORDER, 4 × SC 13G/A and 3 other forms
Counted, not listed; the year is on EDGAR.
2015 · 143 filings — 126 × 4, 6 × CT ORDER, 4 × SC 13G/A and 5 other forms
Counted, not listed; the year is on EDGAR.
2014 · 157 filings — 126 × 4, 10 × CT ORDER, 6 × 5 and 7 other forms
Counted, not listed; the year is on EDGAR.
2013 · 106 filings — 91 × 4, 4 × CT ORDER, 3 × SC 13G and 5 other forms
Counted, not listed; the year is on EDGAR.
2012 · 132 filings — 108 × 4, 10 × CT ORDER, 3 × CORRESP and 6 other forms
Counted, not listed; the year is on EDGAR.
2011 · 109 filings — 70 × 4, 10 × CT ORDER, 6 × 4/A and 13 other forms
Counted, not listed; the year is on EDGAR.
2010 · 101 filings — 83 × 4, 7 × CT ORDER, 2 × 4/A and 7 other forms
Counted, not listed; the year is on EDGAR.
2009 · 125 filings — 97 × 4, 6 × SC TO-T/A, 5 × CT ORDER and 9 other forms
Counted, not listed; the year is on EDGAR.
2008 · 132 filings — 111 × 4, 5 × 4/A, 3 × SC 13G/A and 8 other forms
Counted, not listed; the year is on EDGAR.
2007 · 127 filings — 107 × 4, 5 × 3, 5 × 424B7 and 6 other forms
Counted, not listed; the year is on EDGAR.
2006 · 120 filings — 95 × 4, 4 × CORRESP, 4 × SC TO-C and 10 other forms
Counted, not listed; the year is on EDGAR.
2005 · 74 filings — 65 × 4, 4 × 3, 1 × 4/A and 4 other forms
Counted, not listed; the year is on EDGAR.
2004 · 75 filings — 66 × 4, 2 × 3, 2 × 4/A and 4 other forms
Counted, not listed; the year is on EDGAR.
2003 · 62 filings — 36 × 4, 4 × POS AM, 4 × SC 13G/A and 9 other forms
Counted, not listed; the year is on EDGAR.
2002 · 11 filings — 4 × SC 13G/A, 2 × 424B3, 1 × SC 13D and 4 other forms
Counted, not listed; the year is on EDGAR.
2001 · 16 filings — 10 × 424B3, 2 × SC 13G/A, 1 × S-3 and 3 other forms
Counted, not listed; the year is on EDGAR.
2000 · 9 filings — 3 × SC 13G, 3 × SC 13G/A, 1 × DEFS14A and 2 other forms
Counted, not listed; the year is on EDGAR.
1999 · 14 filings — 4 × SC 13G/A, 3 × SC 13G, 2 × S-8 and 5 other forms
Counted, not listed; the year is on EDGAR.
1998 · 13 filings — 7 × SC 13G, 5 × SC 13G/A, 1 × S-8
Counted, not listed; the year is on EDGAR.
1997 · 5 filings — 4 × SC 13G/A, 1 × SC 13G
Counted, not listed; the year is on EDGAR.
1996 · 6 filings — 2 × S-8, 2 × SC 13G, 2 × SC 13G/A
Counted, not listed; the year is on EDGAR.
1995 · 1 filing — 1 × SC 13G
Counted, not listed; the year is on EDGAR.
1994 · 3 filings — 3 × SC 13G/A
Counted, not listed; the year is on EDGAR.
About this data#
Gilead Sciences Inc. (GILD) has 3,169 filings on EDGAR going back to 1994: 34 annual reports, 94 quarterly reports and 317 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 24, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Aug 4, 2026, furnished a press release headed “GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS”. Over the last 13 months insiders sold $70.7M in 32 sales and bought nothing on the open market; 110 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Gilead Sciences Inc., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read GILD's latest 10-K?
- GILD's latest annual report, a 10-K, was filed on Feb 24, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did GILD last file an 8-K?
- On Aug 4, 2026 it furnished a press release headed “GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS”. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Aug 4, 2026.
- Are GILD insiders buying or selling?
- Over the last 13 months insiders sold $70.7M in 32 sales and bought nothing on the open market; 110 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: O'Day Daniel Patrick (Chairman & CEO · Director) sold 15,000 shares on Oct 1, 2026 for $2.2M, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has GILD made?
- 3,169 filings are on EDGAR under the registrant records that have been Gilead Sciences Inc., going back to 1994; 2,126 of them are insider ownership forms (Forms 3, 4, 5 and 144).